IV is a prospective, randomized (1:1, Absorb BVS to XIENCE), single-blind, multi-center study, registering approximately 3000 subjects at approximately 140 sites. ABSORBIV is a continuation of ABSORB III (NCT01751906) trial which are maintained under one protocol because both trial designs are related. The data from ABSORB III and ABSORBIV will be pooled to support the ABSORBIV primary endpoint. Both the trials will evaluate the safety and effectiveness of Absorb BVS.
Absorb BVS; Device: XIENCE
Primary Investigator: Broderick